retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% 🎙️ NEW EPISODE: Retatrutide—The Triple

Melanotan II a drug that never made it through clinical trials

Int J Pept Protein Res 1992;40:33343.ArticlePubMed 35

This product is not a medicine, medical device, or dietary supplement

Haittavaikutukset liittyvt usein ruoansulatuskanavaan Tavallisimpia haittavaikutuksia ovat: pahoinvointi vatsakipu ripuli ummetus oksentelu Oireet ovat usein voimakkaimmillaan hoidon alkuvaiheessa tai annosta suurennettaessa

And current data reiterates the potential benefits of GLP-1 drugs for weight loss, with a recent study finding that medications like Wegovy that are prescribed for weight loss may reduce the risk of heart attack, stroke or heart-related death in people with cardiovascular disease

If you are also taking insulin or sulfonylureas and experiencing reduced food intake due to digestive symptoms, monitor your blood glucose closely as you may be at risk of hypoglycaemia